Cargando…

Polysomy of chromosome 17 in breast cancer tumors showing an overexpression of ERBB2: a study of 175 cases using fluorescence in situ hybridization and immunohistochemistry

INTRODUCTION: One of the most common genetic aberrations associated with breast cancer is the amplification and overexpression of the ERBB2 proto-oncogene located at chromosome 17, bands q12-21. The amplification/overexpression occurs in 25 to 30% of all breast cancers. In breast cancer, aneusomy of...

Descripción completa

Detalles Bibliográficos
Autores principales: Salido, Marta, Tusquets, Ignasi, Corominas, Josep M, Suarez, Marta, Espinet, Blanca, Corzo, Cristina, Bellet, Meritxell, Fabregat, Xavier, Serrano, Sergi, Solé, Francesc
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2005
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1064140/
https://www.ncbi.nlm.nih.gov/pubmed/15743507
http://dx.doi.org/10.1186/bcr996
_version_ 1782123306943512576
author Salido, Marta
Tusquets, Ignasi
Corominas, Josep M
Suarez, Marta
Espinet, Blanca
Corzo, Cristina
Bellet, Meritxell
Fabregat, Xavier
Serrano, Sergi
Solé, Francesc
author_facet Salido, Marta
Tusquets, Ignasi
Corominas, Josep M
Suarez, Marta
Espinet, Blanca
Corzo, Cristina
Bellet, Meritxell
Fabregat, Xavier
Serrano, Sergi
Solé, Francesc
author_sort Salido, Marta
collection PubMed
description INTRODUCTION: One of the most common genetic aberrations associated with breast cancer is the amplification and overexpression of the ERBB2 proto-oncogene located at chromosome 17, bands q12-21. The amplification/overexpression occurs in 25 to 30% of all breast cancers. In breast cancer, aneusomy of chromosome 17, either monosomy or polysomy, is frequently observed by conventional cytogenetics and fluorescence in situ hybridization (FISH). The aim of this study was to discover whether or not numerical aberrations on chromosome 17 have a correlation to the amplification or overexpression of the ERBB2 gene and to analyze their clinical implications in subgroups showing 2+ or 3+ positive scores by immunohistochemistry (IHC). METHODS: We used FISH on a series of 175 formalin-fixed paraffin-embedded breast carcinomas to detect ERBB2 amplification, using a dual-probe system for the simultaneous enumeration of the ERBB2 gene and the centromeric region of chromosome 17, as well as using IHC to detect overexpression. We analyzed clinical and pathological variables in a subgroup of patients with 2+ and 3+ IHC scores (147 patients), to describe any differences in clinicopathological characteristics between polysomic and non-polysomic cases with the use of the χ(2 )test. RESULTS: We found 13% of cases presenting polysomy, and three cases presented monosomy 17 (2%). According to the status of the ERBB2 gene, instances of polysomy 17 were more frequently observed in non-amplified cases than in FISH-amplified cases, suggesting that the mechanism for ERBB2 amplification is independent of polysomy 17. Polysomy 17 was detected in patients with 2+ and 3+ IHC scores. We found that nodal involvement was more frequent in polysomic than in non-polysomic cases (P = 0.046). CONCLUSIONS: The determination of the copy number of chromosome 17 should be incorporated into the assesment of ERBB2 status. It might also be helpful to differentiate a subgroup of breast cancer patients with polysomy of chromosome 17 and overexpression of ERBB2 protein that probably have genetic and clinical differences.
format Text
id pubmed-1064140
institution National Center for Biotechnology Information
language English
publishDate 2005
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-10641402005-03-11 Polysomy of chromosome 17 in breast cancer tumors showing an overexpression of ERBB2: a study of 175 cases using fluorescence in situ hybridization and immunohistochemistry Salido, Marta Tusquets, Ignasi Corominas, Josep M Suarez, Marta Espinet, Blanca Corzo, Cristina Bellet, Meritxell Fabregat, Xavier Serrano, Sergi Solé, Francesc Breast Cancer Res Research Article INTRODUCTION: One of the most common genetic aberrations associated with breast cancer is the amplification and overexpression of the ERBB2 proto-oncogene located at chromosome 17, bands q12-21. The amplification/overexpression occurs in 25 to 30% of all breast cancers. In breast cancer, aneusomy of chromosome 17, either monosomy or polysomy, is frequently observed by conventional cytogenetics and fluorescence in situ hybridization (FISH). The aim of this study was to discover whether or not numerical aberrations on chromosome 17 have a correlation to the amplification or overexpression of the ERBB2 gene and to analyze their clinical implications in subgroups showing 2+ or 3+ positive scores by immunohistochemistry (IHC). METHODS: We used FISH on a series of 175 formalin-fixed paraffin-embedded breast carcinomas to detect ERBB2 amplification, using a dual-probe system for the simultaneous enumeration of the ERBB2 gene and the centromeric region of chromosome 17, as well as using IHC to detect overexpression. We analyzed clinical and pathological variables in a subgroup of patients with 2+ and 3+ IHC scores (147 patients), to describe any differences in clinicopathological characteristics between polysomic and non-polysomic cases with the use of the χ(2 )test. RESULTS: We found 13% of cases presenting polysomy, and three cases presented monosomy 17 (2%). According to the status of the ERBB2 gene, instances of polysomy 17 were more frequently observed in non-amplified cases than in FISH-amplified cases, suggesting that the mechanism for ERBB2 amplification is independent of polysomy 17. Polysomy 17 was detected in patients with 2+ and 3+ IHC scores. We found that nodal involvement was more frequent in polysomic than in non-polysomic cases (P = 0.046). CONCLUSIONS: The determination of the copy number of chromosome 17 should be incorporated into the assesment of ERBB2 status. It might also be helpful to differentiate a subgroup of breast cancer patients with polysomy of chromosome 17 and overexpression of ERBB2 protein that probably have genetic and clinical differences. BioMed Central 2005 2005-01-26 /pmc/articles/PMC1064140/ /pubmed/15743507 http://dx.doi.org/10.1186/bcr996 Text en Copyright © 2005 Salido et al.; licensee BioMed Central Ltd.
spellingShingle Research Article
Salido, Marta
Tusquets, Ignasi
Corominas, Josep M
Suarez, Marta
Espinet, Blanca
Corzo, Cristina
Bellet, Meritxell
Fabregat, Xavier
Serrano, Sergi
Solé, Francesc
Polysomy of chromosome 17 in breast cancer tumors showing an overexpression of ERBB2: a study of 175 cases using fluorescence in situ hybridization and immunohistochemistry
title Polysomy of chromosome 17 in breast cancer tumors showing an overexpression of ERBB2: a study of 175 cases using fluorescence in situ hybridization and immunohistochemistry
title_full Polysomy of chromosome 17 in breast cancer tumors showing an overexpression of ERBB2: a study of 175 cases using fluorescence in situ hybridization and immunohistochemistry
title_fullStr Polysomy of chromosome 17 in breast cancer tumors showing an overexpression of ERBB2: a study of 175 cases using fluorescence in situ hybridization and immunohistochemistry
title_full_unstemmed Polysomy of chromosome 17 in breast cancer tumors showing an overexpression of ERBB2: a study of 175 cases using fluorescence in situ hybridization and immunohistochemistry
title_short Polysomy of chromosome 17 in breast cancer tumors showing an overexpression of ERBB2: a study of 175 cases using fluorescence in situ hybridization and immunohistochemistry
title_sort polysomy of chromosome 17 in breast cancer tumors showing an overexpression of erbb2: a study of 175 cases using fluorescence in situ hybridization and immunohistochemistry
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1064140/
https://www.ncbi.nlm.nih.gov/pubmed/15743507
http://dx.doi.org/10.1186/bcr996
work_keys_str_mv AT salidomarta polysomyofchromosome17inbreastcancertumorsshowinganoverexpressionoferbb2astudyof175casesusingfluorescenceinsituhybridizationandimmunohistochemistry
AT tusquetsignasi polysomyofchromosome17inbreastcancertumorsshowinganoverexpressionoferbb2astudyof175casesusingfluorescenceinsituhybridizationandimmunohistochemistry
AT corominasjosepm polysomyofchromosome17inbreastcancertumorsshowinganoverexpressionoferbb2astudyof175casesusingfluorescenceinsituhybridizationandimmunohistochemistry
AT suarezmarta polysomyofchromosome17inbreastcancertumorsshowinganoverexpressionoferbb2astudyof175casesusingfluorescenceinsituhybridizationandimmunohistochemistry
AT espinetblanca polysomyofchromosome17inbreastcancertumorsshowinganoverexpressionoferbb2astudyof175casesusingfluorescenceinsituhybridizationandimmunohistochemistry
AT corzocristina polysomyofchromosome17inbreastcancertumorsshowinganoverexpressionoferbb2astudyof175casesusingfluorescenceinsituhybridizationandimmunohistochemistry
AT belletmeritxell polysomyofchromosome17inbreastcancertumorsshowinganoverexpressionoferbb2astudyof175casesusingfluorescenceinsituhybridizationandimmunohistochemistry
AT fabregatxavier polysomyofchromosome17inbreastcancertumorsshowinganoverexpressionoferbb2astudyof175casesusingfluorescenceinsituhybridizationandimmunohistochemistry
AT serranosergi polysomyofchromosome17inbreastcancertumorsshowinganoverexpressionoferbb2astudyof175casesusingfluorescenceinsituhybridizationandimmunohistochemistry
AT solefrancesc polysomyofchromosome17inbreastcancertumorsshowinganoverexpressionoferbb2astudyof175casesusingfluorescenceinsituhybridizationandimmunohistochemistry